When they used these two signatures to query archived gene expression profiles of lung adenocarcinomas, they found the same results for patients with hepatocellular carcinoma (patients with a late TGFβ signature had significantly shortened median survival time compared to patients who had an early TGFβ signature). This evidence concerns the gene TGFB1 and hepatocellular carcinoma.